Now Available: United Arab Emirates Pharmaceuticals & Healthcare Report Q3 2010

July 4, 2010 - PRLog -- In 2009, the UAE pharmaceutical market reached a value of AED5.08bn (US$1.38bn). In 2010, we forecast the drug market will be worth AED5.84bn (US$1.59bn), experiencing a growth of 14.9%. By 2014, we calculate drug expenditure reaching a value of AED9.04bn (US$2.46bn), equating to a compound annual growth rate (CAGR) of 12.21%. Over the 2009-2019 forecast period, we calculate that drug expenditure will reach AED13.19bn (US$3.59bn), equating to a CAGR of 10.01%.

Most of the value development will be realised in the prescription sector, boosted by rising population numbers and a changing diseases profile. In particular, the country is tackling an obesity and diabetes epidemic, which will also require the long-term treatment of related conditions, such as increased blood pressure. Additionally, the recently established single market of the six Gulf Cooperation States (GCC) states (Saudi Arabia, Oman, Qatar, Bahrain, the UAE and Kuwait) will facilitate the placement of foreign products in the region.

The UAE has continued to improve its business environment and make concerted efforts to maintain and increase foreign direct investment (FDI) into manufacturing and diversifying the economy. For the pharmaceutical sector, this has been relatively successful, particularly with the DuBiotech complex and the ongoing construction of health cities and complexes. Also, healthcare reforms in the region have increased the potential for higher per-capita spending on medicines, while government budgets allocated to pharmaceuticals have also increased.

While the Middle East holds great potential for drugmakers in terms of sales, especially in the generic drug sector, local manufacturing needs greater investment in order to meet demand and stay competitive with regional rivals, especially in terms of price. One of the UAE's oldest drugmakers, Julphar, only distributes 10% of its output within the Emirates, focusing the rest on exports. Since the UAE is likely to have limited domestic demand in the medium and long term, this strategy is particularly wise.

However, Egypt, Jordan and Saudi Arabia are providing more competition for generic pharmaceutical firms, though BMI notes that this can be largely attributed to high local demand which has necessitated and supported the growth of local drugmakers. By contrast, the UAE pharmaceutical firms have to rely on exports for revenue growth. This is not entirely bad - local drugmakers in the country are geared toward this business model, but the UAE is nonetheless still heavily reliant on imported medicines, which then points to a lack of diversification within the local drug manufacturing sector.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/71507_united_arab_emirates_pha...

Report Table of Contents:

Executive Summary
SWOT Analysis
- United Arab Emirates Pharmaceuticals And Healthcare Industry SWOT
- United Arab Emirates Political SWOT
- United Arab Emirates Economic SWOT
- United Arab Emirates Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q310
- Limits to Potential Returns
- Risks To Realisation Of Returns
UAE - Market Summary
- Regulatory Environment
- Recent Regulatory Developments
- Pharmaceutical Advertising
- Intellectual Property Regime
- Counterfeit Medicines
- Pricing And Reimbursement Regime
- Recent Pricing and Reimbursement Developments
- Regional Harmonisation
- Free Trade Agreements
Industry Trends and Developments
- Epidemiology
- Healthcare Sector
- Healthcare Sector Reforms
- Recent Healthcare Sector Developments
- Hospital Sector Developments
- Health Insurance
- Recent Health Insurance Industry Developments
- Health Tourism
- Domestic Pharmaceutical Sector
- Foreign Companies
- Company Developments
- Pharmaceutical Distribution and Retail
- Recent Developments in Pharmaceutical Distribution and Retail
- Research and Development
- DuBiotech
- Medical Devices
- Recent Developments in the Medical Devices Market
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Macroeconomic Scenario
- Table: United Arab Emirates - Economic Activity
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Pharmaceutical Trade Forecast
- Medical Device Market Forecast
- Other Healthcare Forecasts
- Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
- Indigenous Manufacturers
- Gulf Pharmaceutical Industries (Julphar)
- Globalpharma
- Modern Pharmaceutical Company (MPC)
- NeoPharma
- Leading Foreign Companies
- GlaxoSmithKline
- Pfizer
- Novartis
- Johnson & Johnson (J&J)
- Sanofi-Aventis
- Abbott Laboratories
- Merck & Co
Country Snapshot: UAE Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2000-2004
- Table: Consumer Expenditure, 2000-2012 (US$)
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.